MCID: OVR049
MIFTS: 50

Ovarian Disease

Categories: Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Disease

MalaCards integrated aliases for Ovarian Disease:

Name: Ovarian Disease 12 6 15 17
Ovarian Dysfunction 12 54 15 17 32
Ovarian Diseases 54 44 70
Disorder of Endocrine Ovary 70
Ovarian Disorders 42

Classifications:



External Ids:

Disease Ontology 12 DOID:1100 DOID:1414
ICD9CM 34 256.3
MeSH 44 D010049
NCIt 50 C26841
SNOMED-CT 67 267399006 5552004
ICD10 32 E28 E28.3 E28.9
UMLS 70 C0029697 C0029928 C0154208

Summaries for Ovarian Disease

MedlinePlus : 42 The ovaries are part of the female reproductive system. Women have two ovaries, one on each side of the uterus. Each ovary is about the size and shape of an almond. The ovaries produce and store a woman's eggs. During ovulation, an ovary releases an egg. If that egg is fertilized by a sperm, a pregnancy can occur. Ovaries also make the female hormones estrogen and progesterone. When a woman goes through menopause, her ovaries stop making those hormones and releasing eggs. Problems with the ovaries include Ovarian cancer Ovarian cysts and polycystic ovary syndrome Primary ovarian insufficiency Ovarian torsion, a twisting of the ovary

MalaCards based summary : Ovarian Disease, also known as ovarian dysfunction, is related to polycystic ovary syndrome and estrogen excess, and has symptoms including pelvic pain and mittelschmerz. An important gene associated with Ovarian Disease is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Transcription_Role of VDR in regulation of genes involved in osteoporosis and Follicle Stimulating Hormone (FSH) signaling pathway. The drugs Bevacizumab and Angiogenesis Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include ovary, pituitary and uterus, and related phenotypes are endocrine/exocrine gland and reproductive system

Disease Ontology : 12 An ovarian disease that is characterized by irregular or absent ovulation.

Wikipedia : 73 Ovarian diseases are conditions that happen to young women which can affect their reproductive system... more...

Related Diseases for Ovarian Disease

Diseases in the Ovarian Disease family:

Primary Ovarian Insufficiency 2a Primary Ovarian Insufficiency 2b
Primary Ovarian Insufficiency 3 Primary Ovarian Insufficiency 4
Primary Ovarian Insufficiency 5 Primary Ovarian Insufficiency 6
Primary Ovarian Insufficiency 7 Primary Ovarian Insufficiency 8
Primary Ovarian Insufficiency 9 Primary Ovarian Insufficiency 10
Primary Ovarian Insufficiency 11 Primary Ovarian Insufficiency 12
Primary Ovarian Insufficiency 13 Primary Ovarian Insufficiency 14
Primary Ovarian Insufficiency 15 Primary Ovarian Insufficiency 16
Primary Ovarian Insufficiency 17 Ovarian Insufficiency, Familial

Diseases related to Ovarian Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 319)
# Related Disease Score Top Affiliating Genes
1 polycystic ovary syndrome 32.6 SHBG PRL INS IGFBP1 IGF1 GNRH1
2 estrogen excess 32.5 SHBG PRL GNRH1 FSHR FOXL2 CYP19A1
3 ovarian cyst 32.3 PRL MUC16 GNRH1 FOXL2 CYP19A1 AMH
4 anovulation 32.3 SHBG PRL INS IGFBP1 IGF1 GNRH1
5 ovarian hyperstimulation syndrome 32.3 SHBG INS GNRH1 FSHR CYP19A1 CGA
6 premature menopause 32.2 ZP3 STAG3 SHBG PRL INS IGF1
7 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 32.1 INS IGF1
8 hyperinsulinism 31.5 SHBG INS IGFBP1 IGF1 GNRH1
9 hyperandrogenism 31.5 SHBG PRL INS IGFBP1 IGF1 GNRH1
10 amenorrhea 31.3 SHBG PRL INS IGF1 GNRH1 GDF9
11 hyperprolactinemia 31.3 SHBG PRL INS IGF1 GNRH1
12 acanthosis nigricans 31.2 SHBG PRL INS IGF1
13 infertility 31.1 ZP3 STAG3 SHBG PRL INS IGFBP1
14 insulin-like growth factor i 31.1 SHBG PRL INS IGFBP1 IGF1
15 acne 31.0 TNF SHBG PRL INS IGF1
16 endometriosis 30.8 MUC16 MIR199A1 MIR141 IGFBP1 GNRH1 CYP19A1
17 body mass index quantitative trait locus 11 30.8 TNF SHBG MIR483 MIR199A1 INS IGFBP1
18 premature ovarian failure 1 30.8 STAG3 FMR1 CYP19A1
19 hypogonadotropic hypogonadism 30.8 SHBG PRL INS GNRH1 CYP19A1 AMH
20 mccune-albright syndrome 30.7 PRL IGF1 CYP19A1 AMH
21 precocious puberty 30.7 GNRH1 FSHR CYP19A1
22 hypogonadism 30.7 SHBG PRL INS IGF1 GNRH1
23 pituitary gland disease 30.7 PRL INS IGF1 GNRH1 CGA
24 luteoma 30.7 SHBG FSHR FOXL2 CYP19A1 CGA
25 gestational diabetes 30.6 TNF SHBG INS IGFBP1
26 galactorrhea 30.6 PRL IGF1
27 gonadal dysgenesis 30.6 SHBG GDF9 FSHR FOXL2 AMH
28 endometrial cancer 30.6 SHBG MUC16 MIR199A1 INS IGFBP1 IGF1
29 oligospermia 30.6 PRL GNRH1 AMH
30 hyperthyroidism 30.5 SHBG PRL INS IGF1 CGA
31 corpus luteum cyst 30.5 MUC16 GNRH1 FOXL2
32 hypothyroidism 30.5 TNF SHBG PRL INS IGF1 GNRH1
33 prader-willi syndrome 30.5 TNF PRL INS IGFBP1 IGF1 GNRH1
34 turner syndrome 30.5 SHBG INS IGFBP1 IGF1 FMR1 AMH
35 vaginal discharge 30.5 TNF GNRH1 CYP19A1
36 osteoporosis 30.5 TNF SHBG PRL INS IGFBP1 IGF1
37 myoma 30.5 MUC16 GNRH1 CYP19A1 AMH
38 androgenic alopecia 30.5 SHBG PRL INS IGF1 CYP19A1
39 alopecia 30.5 TNF SHBG PRL IGF1
40 empty sella syndrome 30.5 PRL INS IGF1 GNRH1
41 acromegaly 30.5 SHBG PRL INS IGFBP1 IGF1 GNRH1
42 gynecomastia 30.4 SHBG PRL GNRH1 CYP19A1 CGA
43 anorexia nervosa 30.4 SHBG PRL INS IGFBP1 IGF1
44 chronic salpingo-oophoritis 30.4 PRL AMH
45 endometriosis of ovary 30.4 MIR141 GNRH1 CYP19A1 AMH
46 adenomyosis 30.4 PRL GNRH1 CYP19A1
47 anxiety 30.3 TNF PRL INS FMR1
48 pseudohermaphroditism 30.3 FSHR CYP19A1 AMH
49 alopecia, androgenetic, 1 30.3 SHBG CYP19A1
50 bipolar disorder 30.2 TNF SHBG PRL IGFBP1 IGF1

Graphical network of the top 20 diseases related to Ovarian Disease:



Diseases related to Ovarian Disease

Symptoms & Phenotypes for Ovarian Disease

UMLS symptoms related to Ovarian Disease:


pelvic pain; mittelschmerz

MGI Mouse Phenotypes related to Ovarian Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.8 AMH CGA CYP19A1 FMR1 FOXL2 FSHR
2 reproductive system MP:0005389 9.47 AMH CGA CYP19A1 FMR1 FOXL2 FSHR

Drugs & Therapeutics for Ovarian Disease

Drugs for Ovarian Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3 216974-75-3
2 Angiogenesis Inhibitors Phase 3
3
Polyestradiol phosphate Approved Phase 2 28014-46-2
4
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
5
Ethinyl Estradiol Approved Phase 2 57-63-6 5991
6
Testosterone Approved, Investigational Phase 2 58-22-0 6013
7
Lactitol Approved, Investigational Phase 2 585-86-4 157355
8
Desogestrel Approved Phase 2 54024-22-5 40973
9
Spironolactone Approved Phase 2 1952-01-7, 52-01-7 5833
10
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
11
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
13
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
14
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
15
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
16
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
17
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
18
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
19
Olaparib Approved Phase 2 763113-22-0 23725625
20
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
21
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
22
Pembrolizumab Approved Phase 2 1374853-91-4
23
Lenvatinib Approved, Investigational Phase 2 417716-92-8
24 Estradiol 3-benzoate Phase 2
25 Hormones Phase 2
26 Estradiol 17 beta-cypionate Phase 2
27 Contraceptives, Oral Phase 2
28 Hormone Antagonists Phase 2
29 Contraceptives, Oral, Combined Phase 2
30 Contraceptive Agents Phase 2
31 Androgens Phase 2
32 Estrogens Phase 2
33 Mineralocorticoids Phase 2
34 Mineralocorticoid Receptor Antagonists Phase 2
35 diuretics Phase 2
36 Antineoplastic Agents, Hormonal Phase 2
37 Diuretics, Potassium Sparing Phase 2
38 Gastrointestinal Agents Phase 2
39 Alkylating Agents Phase 2
40 Antiemetics Phase 2
41 glucocorticoids Phase 2
42 Antifungal Agents Phase 2
43 taxane Phase 2
44 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
45 insulin Phase 2
46 Insulin, Globin Zinc Phase 2
47 Analgesics, Non-Narcotic Phase 2
48 Salicylsalicylic acid Phase 2
49 Sodium salicylate Phase 2 54-21-7
50 Analgesics Phase 2

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Active, not recruiting NCT01462890 Phase 3 Paclitaxel;Carboplatin
2 A Prospective, Controlled, Randomized, Multi-Center, Exploratory Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil Unknown status NCT00544310 Phase 1, Phase 2
3 Phase II Study of Four Dose Levels of Intraperitoneal NanoPac® Plus IV Carboplatin and Paclitaxel in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery Completed NCT03029585 Phase 2 NanoPac® 100 mg/m2;NanoPac® 200 mg/m2;NanoPac® 300 mg/m2;NanoPac® 400 mg/m2;Standard of Care Intravenous Chemotherapy
4 Prospective Randomized Controlled Trial of Antral Follicle Priming Prior to IVF-ICSI in Previously Diagnosed Low Responders. Completed NCT01310647 Phase 2 Testosterone;Estradiol;CombEq
5 Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome Completed NCT00004311 Phase 2 leuprolide acetate;spironolactone
6 Phase 2 Study of Efficacy and Safety of Trabectedin in Subjects With Advanced Ovarian Cancer Completed NCT00050414 Phase 2 Trabectedin;Dexamethasone
7 Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma Completed NCT01460979 Phase 2 Temsirolimus
8 A Phase II, Randomized Study of Cytoreductive Surgery Combined With Niraparib Maintenance in Platinum-sensitive, Secondary Recurrent Ovarian Cancer Recruiting NCT03983226 Phase 2 carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...;Niraparib
9 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction Recruiting NCT03229408 Phase 2 Salsalate
10 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Recruiting NCT03562897 Phase 2
11 A Single-arm, Prospective, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Recruiting NCT04556071 Phase 2 Niraparib;Bevacizumab
12 A Prospective, Single-arm, Single-center, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Recruiting NCT04566952 Phase 2 Anlotinib;Olaparib
13 A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Not yet recruiting NCT04807166 Phase 2 Drug: Anlotinib;Drug: Carboplatin/Paclitaxel
14 A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer Not yet recruiting NCT04519151 Phase 2 Pembrolizumab;Lenvatinib
15 A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Terminated NCT03146663 Phase 2 NUC-1031 500 mg;NUC-1031 750mg
16 89Zr-MMOT0530A PET Imaging in Patients With Unresectable Pancreatic or Platinum-resistant Ovarian Cancer Before Treatment With DMOT4039A. A Separate Study to the Phase I Study Protocol DMO4993g Completed NCT01832116 Phase 1 89Zr-MMOT0530A
17 A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-8M4 Given as Monotherapy in Subjects With Advanced Ovarian Cancer Completed NCT00816764 Phase 1
18 A Phase 1b, Parallel Arm, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Two Different Chemotherapy Regimens in Women With Platinum Resistant or Platinum Sensitive Ovarian Cancer Terminated NCT01016054 Phase 1 Pegylated liposomal doxorubicin (PLD);gemcitabine;carboplatin
19 The Role of Pelvic Microbiomes During the Malignant Transformation of Benign Ovarian Diseases Unknown status NCT03388996
20 The Role of Inactive Follicle Stimulating Hormone in Ovarian Dysfunction in Galactosemia Unknown status NCT00619333 follitropin and lutropin
21 Phenotyping and Genotyping of Women Presenting With Ovarian Dysfunction Associated With a Hypergonadotropic Hypo-estrogenic Hormonal Status (WHO III) and Their First and Second Degree Relatives Unknown status NCT01411644
22 A Feasibility Study of Elemental Diet as an Alternative to Parenteral Nutrition for Patients With Inoperable Malignant Bowel Obstruction Unknown status NCT03150992
23 Pathogenesis of Functional Hypothalamic Amenorrhea Completed NCT01674426
24 Evaluation of Ovarian Reserve Using Anti-müllerian Hormone and Antral Follicle Count in Ankylosing Spondylitis: Preliminary Study Completed NCT04209881
25 Feasability of Transgastric Adnexectomy Completed NCT01566955
26 Comparison of 2 Techniques of Invasive Mini Surgery: Coelioscopy Mini-trocar and Monotrocar in the Adnexa no Carcinologic Surgery : Forward-looking Observational Study. Completed NCT02885779
27 Timing of Development in Embryos Derived From Women With Polycystic Ovairan Syndrome and Controls Completed NCT01953146
28 The nCYT Study: A Powered Study to Evaluate the Sensitivity and Specificity of Cytological Evaluation of Fallopian Tube Samples Collected by the Cytuity in Determining the Presence of Malignancy Completed NCT03593681
29 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country. Completed NCT00210249
30 Turner Syndrome Minipuberty Study A Prospective, Descriptive Cohortstudy Recruiting NCT04189406
31 Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer: Prospective Study of Pharmacokinetics Patterns and Underlying Biology Active, not recruiting NCT02973750
32 Added Value of Ovarian-Adnexal Reporting and Data System in Evaluation of Ovarian Lesions Not yet recruiting NCT04579575
33 Ovarian Cancer Early Detection Screening Program Terminated NCT01292733 Early Phase 1

Search NIH Clinical Center for Ovarian Disease

Cochrane evidence based reviews: ovarian diseases

Genetic Tests for Ovarian Disease

Anatomical Context for Ovarian Disease

MalaCards organs/tissues related to Ovarian Disease:

40
Ovary, Pituitary, Uterus, Breast, Thyroid, Bone, Placenta

Publications for Ovarian Disease

Articles related to Ovarian Disease:

(show top 50) (show all 2050)
# Title Authors PMID Year
1
A comparison of the efficacy and safety of traditional Chinese medicine in preconditioning patients with diminished ovarian reserve that would undergo In Vitro fertilization: A network meta-analysis protocol. 42
33530240 2021
2
ARID1A protein expression is retained in ovarian endometriosis with ARID1A loss-of-function mutations: implication for the two-hit hypothesis. 42
32868822 2020
3
Obesity, Insulin Resistance, and Hyperandrogenism Mediate the Link between Poor Diet Quality and Ovarian Dysmorphology in Reproductive-Aged Women. 42
32629978 2020
4
FSH receptor, KL1/2, P450, and PAPP genes in granulosa-lutein cells from in vitro fertilization patients show a different expression pattern depending on the infertility diagnosis. 54 61
19342032 2010
5
FOXL2 copy number changes in the molecular pathogenesis of BPES: unique cohort of 17 deletions. 54 61
20232352 2010
6
Towards a functional classification of pathogenic FOXL2 mutations using transactivation reporter systems. 54 61
19515849 2009
7
Premature ovarian failure and fragile X female premutation carriers: no evidence for a skewed X-chromosome inactivation pattern. 54 61
19373114 2009
8
Characterization of functionally typical and atypical types of polycystic ovary syndrome. 61 54
19240152 2009
9
FOXL2 mutations and genomic rearrangements in BPES. 54 61
18726931 2009
10
A distribution of two SNPs in exon 10 of the FSHR gene among the women with a diminished ovarian reserve in Ukraine. 61 54
19031050 2009
11
Ovarian dysfunction and FMR1 alleles in a large Italian family with POF and FRAXA disorders: case report. 61 54
17428316 2007
12
A novel polyalanine expansion in FOXL2: the first evidence for a recessive form of the blepharophimosis syndrome (BPES) associated with ovarian dysfunction. 54 61
17089161 2007
13
The empty follicle syndrome. 61 54
17243533 2006
14
Gonadotropin-releasing hormone (GnRH) and its natural analogues: a review. 61 54
16650469 2006
15
FSH receptor gene polymorphisms have a role for different ovarian response to stimulation in patients entering IVF/ICSI-ET programs. 61 54
16758348 2006
16
Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. 61 54
16361284 2006
17
A new heterozygous mutation of the FOXL2 gene is associated with a large ovarian cyst and ovarian dysfunction in an adolescent girl with blepharophimosis/ptosis/epicanthus inversus syndrome. 61 54
16131596 2005
18
Premature ovarian failure and forkhead transcription factor FOXL2: blepharophimosis-ptosis-epicanthus inversus syndrome and ovarian dysfunction. 61 54
16208278 2005
19
Recurrent severe hyperandrogenism during pregnancy: a case report. 61 54
15790717 2005
20
Molecular cloning of porcine growth differentiation factor 9 (GDF-9) cDNA and its role in early folliculogenesis: direct ovarian injection of GDF-9 gene fragments promotes early folliculogenesis. 54 61
15509699 2004
21
Electro-acupuncture reverses nerve growth factor abundance in experimental polycystic ovaries in the rat. 54 61
14671415 2004
22
Pregnancy and renal transplantation. 54 61
15013320 2004
23
The effect of herbal medicine on nerve growth factor in estradiol valerate-induced polycystic ovaries in rats. 54 61
14992541 2003
24
Molecular approach to common causes of female infertility. 61 54
12475548 2002
25
Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction. 54 61
11927624 2002
26
The female and the fragile X reviewed. 54 61
11480913 2001
27
Long-term GnRH analogue treatment is equivalent to laparoscopic laser diathermy in polycystic ovarian syndrome patients with severe ovarian dysfunction. 61 54
11098021 2000
28
Induction of ovulation after gnRH antagonists. 54 61
10972519 2000
29
Gonadotropins and cytokines affect luteal function through control of apoptosis in human luteinized granulosa cells. 61 54
10770207 2000
30
Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. 54 61
10690875 2000
31
Design and evaluation of a ZP3 peptide vaccine in a homologous primate model. 61 54
10321806 1999
32
Treatment of cystic ovarian disease in dairy cows with gonadotrophin-releasing hormone: a field study. 61 54
9990705 1999
33
OVCA (CA125) second generation: technical aspects and serum levels in controls, patients with liver disease, pregnant women and patients with ovarian disease. 54 61
9226027 1997
34
GnRH analog administration in patients with polycystic ovarian disease. 54 61
7589755 1995
35
Regulation of galactose-1-phosphate uridyltransferase gene expression. 54 61
7671960 1995
36
Randomised controlled trial of the use of human chorionic gonadotrophin in recurrent miscarriage associated with polycystic ovaries. 61 54
7947503 1994
37
Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. 61 54
8157196 1994
38
Endocrine features in eutestosteronemic women with polycystic ovaries. 61 54
8150364 1994
39
The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation. 54 61
8150903 1993
40
Effects of ovarian surgery on the dopaminergic and opioidergic control of gonadotropin and prolactin secretion in women with polycystic ovarian disease. 54 61
8291452 1993
41
Ovarian electrocauterization causes LH-regulated but not insulin-regulated endocrine changes. 61 54
7690311 1993
42
Serum levels of insulin-like growth factor binding protein-1 and ovulatory responses to clomiphene citrate in women with polycystic ovarian disease. 54 61
7685718 1993
43
Lipoprotein(a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease. 54 61
1399109 1992
44
Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. 61 54
1633889 1992
45
Androstenedione as a predictor of ovarian hyperstimulation syndrome. 61 54
1430128 1992
46
Pharmacologic manipulation of fertility. 54 61
1555118 1992
47
Clinical applications of GnRH and its analogues. 54 61
18407075 1992
48
Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease. 54 61
1708731 1991
49
Use of combined exogenous gonadotropins and pulsatile gonadotropin-releasing hormone in patients with polycystic ovarian disease. 54 61
1898892 1991
50
A novel regimen of gonadotropin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: controlled restoration of gonadotropin secretion and ovulation induction. 61 54
2245840 1990

Variations for Ovarian Disease

ClinVar genetic disease variations for Ovarian Disease:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 STAG3 NM_001282716.1(STAG3):c.2776C>T (p.Arg926Ter) SNV Likely pathogenic 374000 rs764841861 GRCh37: 7:99801719-99801719
GRCh38: 7:100204096-100204096

Expression for Ovarian Disease

Search GEO for disease gene expression data for Ovarian Disease.

Pathways for Ovarian Disease

GO Terms for Ovarian Disease

Cellular components related to Ovarian Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 AMH CGA GDF9 GNRH1 IGF1 IGFBP1
2 extracellular space GO:0005615 9.47 AMH CGA GDF9 GNRH1 IGF1 IGFBP1
3 Golgi lumen GO:0005796 9.33 CGA INS MUC16

Biological processes related to Ovarian Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.46 PRL INS IGFBP1 IGF1
2 positive regulation of cell proliferation GO:0008284 9.43 CGA GDF9 IGF1 INS MIR141 PRL
3 regulation of osteoclast differentiation GO:0045670 9.37 FSHR TNF
4 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.32 IGF1 MIR199A1
5 gonad development GO:0008406 9.26 FSHR AMH
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 8.92 FSHR IGF1 INS TNF

Molecular functions related to Ovarian Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.1 AMH CGA GNRH1 IGF1 INS PRL

Sources for Ovarian Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....